Dashboard
Manage Tickers

RZLT Rezolute, Inc.


$ 9.81 $ 0.29 (3.04 %)    

Thursday, 30-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 9.44
$ 9.86 x 350
$ 10.10 x 200
-- - --
$ 2.22 - $ 10.04
1,223,579
na
891.77M
$ 35.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

citizens-maintains-market-outperform-on-rezolute-raises-price-target-to-17
Citizens Maintains Market Outperform on Re...
10/29/2025 16:02:10

Citizens analyst Jason N. Butler maintains Rezolute (NASDAQ:RZLT) with a Market Outperform and raises the price target from ...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/06/2025 17:35:26

guggenheim-reiterates-buy-on-rezolute-maintains-15-price-target
Guggenheim Reiterates Buy on Rezolute, Mai...
09/22/2025 12:47:01

Guggenheim analyst Debjit Chattopadhyay reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $15 price target.

maxim-group-maintains-buy-on-rezolute-raises-price-target-to-20
Maxim Group Maintains Buy on Rezolute, Rai...
09/19/2025 16:49:50

Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $15 to $20.

btig-reiterates-buy-on-rezolute-maintains-17-price-target
BTIG Reiterates Buy on Rezolute, Maintains...
09/18/2025 09:40:33

BTIG analyst Julian Harrison reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $17 price target.

rezolute-q4-eps-026-misses-022-estimate
Rezolute Q4 EPS $(0.26) Misses $(0.22) Est...
09/17/2025 20:08:35

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by...

hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Rezo...
09/03/2025 11:12:30

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

rezolute-secures-fda-alignment-on-streamlined-phase-3-uplift-trial-of-ersodetug-for-tumor-hyperinsulinism-study-simplified-to-16-patient-open-label-design-supported-by-sunrize-confirmatory-data-expected-dec-2025
Rezolute Secures FDA Alignment On Streamli...
09/02/2025 10:17:33

Core News & Articles
10 Health Care Stocks Whale Activity In To...
08/13/2025 17:35:30

rezolute-files-prospectus-to-resale-of-13m-shares-of-common-stock-by-selling-stockholders
Rezolute Files Prospectus To Resale Of 1.3...
07/17/2025 21:32:51

-SEC Filing

rezolute-to-present-late-breaking-phase-3-data-on-rare-hypoglycemia-treatment-at-endo-2025
Rezolute to Present Late-Breaking Phase 3 ...
07/09/2025 11:34:02

Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treati...

rezolute-completes-enrollment-in-phase-3-sunrize-study-of-ersodetug-in-patients-with-congenital-hyperinsulinism
Rezolute Completes Enrollment In Phase 3 s...
05/28/2025 12:04:55

rezolute-q3-eps-027-misses-023-estimate
Rezolute Q3 EPS $(0.27) Misses $(0.23) Est...
05/13/2025 20:27:12

Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by...

rezolute-fda-grants-breakthrough-therapy-designation-to-investigational-therapy-ersodetug-for-treatment-of-hypoglycemia-caused-by-tumor-hi
Rezolute: FDA Grants Breakthrough Therapy ...
05/05/2025 12:01:41

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-yearDesignation underscores need for ...

hc-wainwright--co-reiterates-buy-on-rezolute-maintains-14-price-target
HC Wainwright & Co. Reiterates Buy on Rezo...
04/28/2025 17:41:46

HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.

rezolute-thrilled-with-positive-review-of-genetic-disorder-trial-expects-topline-results-in-december
Rezolute 'Thrilled' With Positive Review O...
04/23/2025 19:50:43

Rezolute advances HI drug trial after DMC review and secures $90 million in funding through stock offering to support development.

rezolute-announces-pricing-of-offering-of-90m-at-335-per-share-of-common-stock-and-pre-funded-warrants
Rezolute Announces Pricing Of Offering Of ...
04/23/2025 12:14:17

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/23/2025 12:06:43

rezolute-announces-the-data-monitoring-committees-recommendation-to-continue-phase-3-sunrize-study-as-planned-in-patients-with-congenital-hi-without-an-increase-in-the-study-sample-size
Rezolute Announces The Data Monitoring Com...
04/23/2025 12:03:15

Independent Data Monitoring Committee (the "DMC") recommends continuation of sunRIZE trial as planned with no need to i...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
04/21/2025 17:05:41

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION